HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights – Correction

This press release corrects a press release issued under the same heading on August 14, 2024 by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and Cash Equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected press release is as follows:

MIRAMAR, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to extend healthspan by disrupting the link between inflammation and age-related disease, today reported financial results and recent business highlights for the second quarter ended June 30, 2024.